Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;111(4):3129-3134.
doi: 10.1097/JS9.0000000000002293.

Exploring genes associated with metabolic dysfunction as therapeutic targets for head and neck cancers: a novel strategy

Affiliations

Exploring genes associated with metabolic dysfunction as therapeutic targets for head and neck cancers: a novel strategy

Si-Yue Yin et al. Int J Surg. .

Abstract

Evidence suggests a potential link between metabolic dysfunction and head and neck cancer (HNC). This study investigates the potential causal relationships between metabolic dysfunction and HNC using genetic data. While no significant causal associations were identified between metabolic indicators and HNC risk, the research revealed that inhibition of certain genes could reduce cancer risk. Specifically, inhibiting sodium/glucose cotransporter 2 (SLC5A2) was associated with a decreased risk of HNC and oropharyngeal cancer (OPC), while ATP-sensitive inward rectifier potassium channel 11 inhibition was linked to a reduced risk of oral cavity cancer. Additionally, inhibiting SLC5A1 and voltage-dependent L-type calcium channel subunit beta-2 showed a connection to lower OPC risk. These findings suggest that targeting these genes could offer promising therapeutic strategies for preventing and treating HNC, as well as improving both preoperative and postoperative management in affected patients.

Keywords: Mendelian randomization; drug targets; head and neck cancer; metabolic dysfunction.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1.
Figure 1.
Overview of the study design. MR, Mendelian randomization; eQTL, expression quantitative trait loci; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein–protein interaction; T2D, type 2 diabetes; CHD, coronary heart disease; SNP, single-nucleotide polymorphisms; GWAS, genome-wide association study; HNC, head and neck cancer; LC, laryngeal cancer; OCC, oral cavity cancer; OPC, oropharyngeal cancer.
Figure 2.
Figure 2.
The main methods and operational processes of study. HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein; TG, triglycerides; HDL-C, high-density lipoprotein; DBP, diastolic blood pressure; SBP, systolic blood pressure; HNC, head and neck cancer; T2D, type 2 diabetes; CHD, coronary heart disease; SNP, single-nucleotide polymorphisms; GWAS, genome-wide association study.
Figure 3.
Figure 3.
Forest plot of association of genetically proxied drug targets with risk of HNC and its subtypes. (A) Forest plot of association of genetically proxied lipid-lowering drug targets with risk of HNC and its subtypes. (B) Forest plot of association of genetically proxied hypoglycemic drug targets with risk of HNC and its subtypes. (C) Forest plot of association of genetically proxied hypertensive drug targets with risk of HNC and its subtypes. HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein; TG, triglycerides; HDL-C, high-density lipoprotein; DBP, diastolic blood pressure; SBP, systolic blood pressure; HNC, head and neck cancer; LC, laryngeal cancer; OCC, oral cavity cancer; OPC, oropharyngeal cancer; OR, odd ratio; HMGCR, HMG-CoA reductase; NPC1L1, Niemann–Pick C1-like protein 1; PCSK9, proprotein convertase subtilisin/kexin type 9; APOB, Apolipoprotein B-100; ABCG5, ATP-binding cassette subfamily G member 5; ABCG8, ATP-binding cassette subfamily G member 8; LDLR, LDL receptor; LPL, lipoprotein lipase; PPARG, peroxisome proliferator-activated receptor gamma; ABCC8, ATP-binding cassette sub-family C member 8; CALCR, calcitonin receptor; DPP4, dipeptidyl peptidase 4; GIP, gastric inhibitory polypeptide; GLP1R, glucagon-like peptide 1 receptor; KCNJ11, ATP-sensitive inward rectifier potassium channel 11; PRKAB1, 5′-AMP-activated protein kinase subunit beta-1; RAMP2, receptor activity-modifying protein 2; SLC5A1, sodium/glucose cotransporter 1; SLC5A2, sodium/glucose cotransporter 2; ACE, angiotensin-converting enzyme; ADRA1A, alpha-1A adrenergic receptor; ADRA2B, alpha-2B adrenergic receptor; ADRB1, beta-1 adrenergic receptor; ADRB2, beta-2 adrenergic receptor; CACNA1C, voltage-dependent N-type calcium channel subunit alpha-1C; CACNA2D2, voltage-dependent calcium channel subunit alpha-2/delta-2; CACNB2, voltage-dependent L-type calcium channel subunit beta-2; REN, renin; SLC12A2, solute carrier family 12 member 2; SLC12A3, solute carrier family 12 member 3. Asterisk represents significance result.

Similar articles

References

    1. Liu Y, Han Y, Chen B, et al. A new online dynamic nomogram: construction and validation of an assistant decision-making model for laryngeal squamous cell carcinoma. Front Oncol 2022;12:829761. - PMC - PubMed
    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Ca A Cancer J Clin 2024;74:12–49. - PubMed
    1. Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc Mar 2016;91:386–96. - PubMed
    1. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am 2014;43:1–23. - PubMed
    1. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012;35:2402–11. - PMC - PubMed

LinkOut - more resources